Close
Almac
Achema middle east

Sartorius Stedim Biotech Acquires UK-Based CRO, BioOutsource

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Novartis to Lower Innovative Medicines Price in the US

Novartis, which is a leading global innovative medicines company,...

New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices

President Donald Trump on December 19, 2025, said that...
- Advertisement -

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industries, acquired the Scottish company BioOutsource Ltd. The privately owned company based in Glasgow, UK, has been operating in the biotechnology market since 2007, and in the last twelve months earned revenue of around 9 million euros with approx. 85 employees. The contractual parties agreed not to disclose any further details of the transaction.

BioOutsource provides contract testing services to global biopharmaceutical clients in order to monitor the safety and quality of biologic drugs and vaccines. In particular, the company specializes in offering a comprehensive suite of services for the fast growing biosimilar industry.

Its assays are used in the early phases of drug characterization and comparability and for lot release testing of novel therapeutics. This acquisition will develop SSB’s service offering throughout the drug development pathway.

Latest stories

Related stories

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Novartis to Lower Innovative Medicines Price in the US

Novartis, which is a leading global innovative medicines company,...

New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices

President Donald Trump on December 19, 2025, said that...

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »